Xingkang Jiang^*, Jing Tian, Yong Xu

Canadian Journal of Urology, Vol.32, No.6, pp. 539-540, 2025, DOI:10.32604/cju.2025.073363 - 30 December 2025

Abstract This article has no abstract. More >

Xinke Chai, Shifeng Wu, Qian Shen, Qiulin Huang^*

Oncology Research, Vol.33, No.12, pp. 3731-3752, 2025, DOI:10.32604/or.2025.067546 - 27 November 2025

Abstract Gastric cancer (GC) is a prevalent malignant tumor globally, with high incidence and mortality rates. Advances in understanding molecular mechanisms underlying GC have highlighted the role of microRNAs (miRNAs) in its initiation, progression, and treatment. The Let-7 family, an important class of miRNAs, is closely associated with the biological behaviors of GC. Aberrant expression of various Let-7 family members in GC patients contributes to disease progression, as they target multiple molecular pathways and participate in diverse regulatory mechanisms throughout GC pathogenesis. This article systematically summarizes the expression patterns of Let-7 family members in GC, explores More >

Ji-eun Yu¹, Eunji Ahn², Hanbit Jin², Dongsu Kim^2,*

International Journal of Mental Health Promotion, Vol.27, No.9, pp. 1353-1367, 2025, DOI:10.32604/ijmhp.2025.067407 - 30 September 2025

Abstract Background: Patients with cancer are confronted not only with physical changes and pain but also with significant psychological challenges, including distress, anxiety, and depression, as a consequence of their diagnosis and treatment. This study aimed to identify the factors influencing anxiety or depression in patients with cancer, examine the relationship between the duration since cancer diagnosis and psychological state, and explore the association between these factors and the use of Korean medicine (KM). Methods: This study utilized data from the 2018 Korea Health Panel spanning 2008 to 2018. The analysis focused on adult participants (aged… More >

JONG-HYUK AHN¹, JIN WOOK YI^2,3,*

Oncology Research, Vol.33, No.8, pp. 1909-1931, 2025, DOI:10.32604/or.2025.065847 - 18 July 2025

Abstract Background: With growing interest in space exploration, understanding microgravity’s impact on human health is essential. This study aims to investigate gene expression changes and migration and invasion potential in five thyroid-related cell lines cultured under simulated microgravity. Methods: Five thyroid-related cell lines—normal thyrocytes (Nthy-ori 3-1), papillary thyroid cancer (PTC) cells (SNU-790, TPC-1), poorly differentiated thyroid cancer cell (BCPAP), and anaplastic thyroid cancer cell (SNU-80)—were cultured under simulated microgravity (10⁻³ g) using a clinostat. Differentially expressed genes (DEGs) were analyzed using cDNA microarray, followed by functional annotation and assessment of aggressiveness via Transwell migration and invasion assays.… More >

PRATIBHA SUKU¹, AISHWARYA DASH¹, ARAVIND RADHAKRISHNAN¹, PANKAJ MALHOTRA², MAN UPDESH SINGH SACHDEVA^1,*

Oncology Research, Vol.33, No.5, pp. 1055-1068, 2025, DOI:10.32604/or.2024.055154 - 18 April 2025

Abstract Circulating plasma cells (CPCs) in patients of plasma cell neoplasm have been an area of intense research in recent decades. Circulating tumor plasma cells (CTPCs) might represent a sub-clone of tumor cells that have exited into peripheral blood as a result of the dynamic interactions between the bone marrow (BM) microenvironment and neoplastic plasma cells. Chemokine receptors like chemokine receptor 4 (CXCR4) and integrins are known to play a role in homing and migration of plasma cells (PCs). The hypoxic microenvironment in the BM niche also contributes to their circulation through various mechanisms. In addition,… More >

Badrinath R. Konety^1,*, Yair Lotan², Amanda Myers³

Canadian Journal of Urology, Vol.32, No.1, pp. 29-36, 2025, DOI:10.32604/cju.2025.064710 - 20 March 2025

Abstract Introduction: Non–muscle-invasive bladder cancer (NMIBC) is a common malignancy worldwide. While Bacillus Calmette-Guérin (BCG) is standard of care for treatment for most patients with high-risk NMIBC, many will either not respond to BCG initially or will eventually develop BCG-unresponsive disease. A treatment option in BCG-unresponsive disease is nadofaragene firadenovec-vncg (Adstiladrin), a nonreplicating adenoviral vector–based gene therapy approved by the US Food and Drug Administration (FDA) for the treatment of adults with high-risk BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors. Objective: To review safety outcomes of participants who received the FDA-approved dose… More >

Peter J. Arnold^1,*, Mabel Spio², Reem Youssef³, Carina Dehner³, Kevin Rice¹

Canadian Journal of Urology, Vol.32, No.1, pp. 47-53, 2025, DOI:10.32604/cju.2025.064694 - 20 March 2025

Abstract Perivascular epithelioid cell tumors (PEComas) are a diverse group of mesenchymal neoplasms. While they have been described throughout the genitourinary system, PEComas are quite rare within the bladder. We present the case of a 37-year-old male who presented in clot retention and was found to have a bladder PEComa. Staging images seemingly demonstrated solid tumor confinement to the bladder and pelvis. Intraoperative pathology revealed peritoneal metastasis. The patient underwent a pelvic mass excision and partial cystectomy. The patient had plans for adjuvant chemotherapy, but later returned to the hospital and passed away from acute hypoxic More >

MOHAMMAD ABOHASSAN, MESFER MOHAMMAD AL SHAHRANI, SARAH KHALED ALOUDA, PRASANNA RAJAGOPALAN^*

Oncology Research, Vol.33, No.3, pp. 675-685, 2025, DOI:10.32604/or.2024.056256 - 28 February 2025

Abstract Background: The JAK2^V617F mutation plays a crucial part in the pathogenesis of myeloproliferative neoplasms (MPN), which includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) leading to aberrant proliferation and survival of hematopoietic cells. Alongside the challenges of drug resistance and side effects, identifying novel compounds that selectively target JAK2^V617F could provide more effective and safer therapeutic options for patients with MPNs. Materials and Methods: We employed computational approaches like high-throughput virtual screening, molecular dynamics simulations (MDS), and binding free energy calculations to identify inhibitors targeting wild and mutant JAK2 kinases. JAK2^V617F positive HEL, wild… More >

Jean-Baptiste Lattouf¹, Jenny J. Ko², Margot K. Davis³, Christian Constance⁴, Geoffrey T. Gotto⁵

Canadian Journal of Urology, Vol.31, No.5, pp. 11977-11985, 2024

Abstract Introduction: Niraparib, a PARP1/2 inhibitor, is newly approved in combination with abiraterone acetate (AA) plus prednisone or prednisolone (niraparib/AA+P) for the treatment of adult patients with BRCA-mutated, treatment-naïve metastatic castration resistant prostate cancer (mCRPC). Detailed guidance beyond the prescribing information may be helpful in managing the side effect profile and dosing practicalities of this combination therapy.
Materials and methods: A panel of specialists convened to design management algorithms for four common niraparib/ AA+P treatment-related adverse events (AEs) in mCRPC; anemia, thrombocytopenia, hypertension, and nausea. The algorithms build on Health Canada-approved prescribing information to highlight practical considerations related… More >

Gabrielle R. Yankelevich¹, Kale Moreland², Makayla M. Swancutt², Robert L. Grubb¹

Canadian Journal of Urology, Vol.31, No.6, pp. 12035-12044, 2024

Abstract Introduction: We report the first scoping review of the clinical urologic literature for photodynamic therapy (PDT) among multiple urologic malignancies.
Materials and methods: A scoping review using Medline and Embase was performed for treatment of urologic malignancies with PDT.
Results: There were 84 papers included with the majority involving bladder and prostate cancer. Upper tract urothelial cancer (UTUC) only comprised three publications and there was no clinical data for renal or testicular cancer. Utilizing PDT in prostate cancer led to a negative biopsy rate of 30%-100%. Bladder cancer treatment with PDT had a 3-month complete response rate of More >